Co-Diagnostics Depreciation & Amortization Growth & History (CODX)
Co-Diagnostics's depreciation and amortization was $1.1M for fiscal 2025.
View full Co-Diagnostics company overviewCo-Diagnostics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.1M | −$270,458 | −19.64% |
| 2024 | 2024-12-31 | $1.4M | $146,792 | +11.93% |
| 2023 | 2023-12-31 | $1.2M | −$52,244 | −4.07% |
| 2022 | 2022-12-31 | $1.3M | $947,355 | +282.49% |
| 2021 | 2021-12-31 | $335,363 | $196,728 | +141.90% |
| 2020 | 2020-12-31 | $138,635 | $72,733 | +110.37% |
| 2019 | 2019-12-31 | $65,902 | $15,137 | +29.82% |
| 2018 | 2018-12-31 | $50,765 | $5,007 | +10.94% |
| 2017 | 2017-12-31 | $45,758 | $8,267 | +22.05% |
| 2016 | 2016-12-31 | $37,491 | — | — |
Co-Diagnostics quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $201,840 | −$89,574 | −30.74% |
| Q1 2026 | 2026-03-31 | $255,445 | −$25,000 | −8.91% |
| Q4 2025 | 2025-12-31 | $267,566 | — | — |
| Q3 2025 | 2025-09-30 | $267,383 | −$83,852 | −23.87% |
| Q2 2025 | 2025-06-30 | $291,414 | −$46,921 | −13.87% |
| Q1 2025 | 2025-03-31 | $280,445 | −$50,128 | −15.16% |
| Q3 2024 | 2024-09-30 | $351,235 | $54,895 | +18.52% |
| Q2 2024 | 2024-06-30 | $338,335 | $33,089 | +10.84% |
| Q1 2024 | 2024-03-31 | $330,573 | $14,563 | +4.61% |
| Q3 2023 | 2023-09-30 | $296,340 | −$16,154 | −5.17% |
| Q2 2023 | 2023-06-30 | $305,246 | −$119,096 | −28.07% |
| Q1 2023 | 2023-03-31 | $316,010 | $68,746 | +27.80% |
| Q3 2022 | 2022-09-30 | $312,494 | $218,456 | +232.31% |
| Q2 2022 | 2022-06-30 | $424,342 | $352,628 | +491.71% |
| Q1 2022 | 2022-03-31 | $247,264 | $180,259 | +269.02% |
| Q3 2021 | 2021-09-30 | $94,038 | $58,548 | +164.97% |
| Q2 2021 | 2021-06-30 | $71,714 | $46,496 | +184.38% |
| Q1 2021 | 2021-03-31 | $67,005 | $46,257 | +222.95% |
| Q3 2020 | 2020-09-30 | $35,490 | $18,484 | +108.69% |
| Q2 2020 | 2020-06-30 | $25,218 | $9,124 | +56.69% |
| Q1 2020 | 2020-03-31 | $20,748 | $7,080 | +51.80% |
| Q3 2019 | 2019-09-30 | $17,006 | $4,390 | +34.80% |
| Q2 2019 | 2019-06-30 | $16,094 | $3,479 | +27.58% |
| Q1 2019 | 2019-03-31 | $13,668 | $1,265 | +10.20% |
| Q3 2018 | 2018-09-30 | $12,616 | $200 | +1.61% |
| Q2 2018 | 2018-06-30 | $12,615 | $1,529 | +13.79% |
| Q1 2018 | 2018-03-31 | $12,403 | $2,677 | +27.52% |
| Q3 2017 | 2017-09-30 | $12,416 | $5,121 | +70.20% |
| Q2 2017 | 2017-06-30 | $11,086 | $2,226 | +25.12% |
| Q1 2017 | 2017-03-31 | $9,726 | — | — |
| Q3 2016 | 2016-09-30 | $7,295 | — | — |
| Q2 2016 | 2016-06-30 | $8,860 | — | — |
Co-Diagnostics depreciation and amortization trends
Over the last five fiscal years, Co-Diagnostics's depreciation and amortization increased from $138,635 to $1.1M, a change of $968,173. The latest reported quarter, Q2 2026, shows $201,840.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Co-Diagnostics source filings ↗